Mercadante 2002.

Methods	Double blind placebo controlled crossover design, two week no washout, carry over effect not analysed
Participants	Neuropathic cancer pain range 4 to 7 on 11 point scale. 16 advanced cancer patients on systemic morphine therapy. Age 55 to 78
Interventions	Amitriptyline up to 50 mg at night for patients < 65 yrs, Amitriptyline up to 30 mg at night for patients > 65 yrs. All patients used Morphine
Outcomes	Opioid consumption, global pain intensity. No significant difference in global pain intensity, least pain intensity or for opioid consumption. Significant difference for worst pain
Notes	No washout so likely to be significant carry over for in first phase Amitriptyline group AEs reported as drowsiness, confusion, dry mouth QS = 3 (R1, DB1, W1)
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear